High prevalence and multifactorial risks of sarcopenia in knee osteoarthritis: a systematic review and meta-analysis

膝骨关节炎患者肌少症的高患病率和多因素风险:系统评价和荟萃分析

阅读:1

Abstract

OBJECTIVE: This study aimed to evaluate the prevalence and risk factors of sarcopenia in patients with knee osteoarthritis (KOA) through a systematic review and meta-analysis. METHODS: A comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, Scopus, China National Knowledge Infrastructure, and WanFang databases for studies published between January 2000 and June 2025. Eligible studies were screened according to predefined inclusion and exclusion criteria. Data were extracted, study quality was assessed, and meta-analyses were performed using Stata 17.0. RESULTS: A total of 35 studies involving 13,528 KOA patients were included, of whom 3597 were diagnosed with sarcopenia. The pooled prevalence of sarcopenia and sarcopenic obesity was 25.07% (95% CI 18.85-31.29%) and 12.06% (95% CI 8.24-15.87%), respectively. Subgroup analyses revealed that sarcopenia prevalence increased with disease severity, reaching 26.01% (95% CI 16.27-35.75%) in patients with Kellgren-Lawrence grade 4 KOA. Prevalence was 25.65% (95% CI 20.30-31.00%) among female and 25.85% (95% CI 18.64-33.06%) among Asian populations. Among patients with osteoporosis and diabetes mellitus, prevalence rates were 21.68% (95% CI 8.84-34.53%) and 28.36% (95% CI 17.43-39.29%), respectively. Additionally, sarcopenia was more common among alcohol consumers (30.72%, 95% CI 15.58-45.86%) and smokers (29.82%, 95% CI 18.87-40.77%), with the prevalence being notably higher at 35.20% (95% CI 28.09-42.31%) among patients with irregular physical activity. CONCLUSION: Sarcopenia and sarcopenic obesity are highly prevalent in patients with KOA and are significantly associated with disease severity, gender, geographic region, comorbidities, and lifestyle factors. These findings highlight the clinical importance of assessing sarcopenia in KOA management. Early screening and timely interventions may improve patient outcomes and quality of life.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。